SML1768
Ximelagatran
≥98% (HPLC), Thrombin inhibitor, powder
别名:
H 376/95, N-[（1R）-1-环己基-2-[（2S）-2-[[[[[[4-[（羟氨基）亚氨基甲基]苯基]甲基]氨基]羰基] -1-氮杂环丁烷基] -2-氧代乙基] -甘氨酸乙酯
产品名称
Ximelagatran, ≥98% (HPLC)
SMILES string
N/C(C1=CC=C(CNC([C@@H]2CCN2C([C@@H](C3CCCCC3)NCC(OCC)=O)=O)=O)C=C1)=N/O
InChI
1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1
InChI key
ZXIBCJHYVWYIKI-PZJWPPBQSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
口服活性凝血酶直接抑制剂；美拉加群的前药。
它同时抑制凝块结合和游离凝血酶。它被小肠迅速吸收，并转化为其活性的二肽药物形式，美拉加群。美拉加群与凝血酶中的精氨酸侧袋结合并使其失活。希美加群的半衰期为 4-5 小时。每天口服两次。
希美加群是口服活性、选择性和有效的直接凝血酶抑制剂。希美加群是凝血酶抑制剂美拉加群的前药。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Erik Sjögren et al.
Pharmaceutical research, 27(4), 597-607 (2010-02-09)
The double prodrug, ximelagatran, is bioconverted, via the intermediates ethylmelagatran and N-hydroxymelagatran, to the direct thrombin inhibitor, melagatran. The primary aim of this study was to investigate the hepatic metabolism and disposition of ximelagatran and the intermediates in pig. A
Ximelagatran (Exanta): alternative to warfarin?
Vaughan C.
Proceedings (Baylor University. Medical Center), 18(1), 76- 80 (2005)
Dukes M N G.
Side Effects of Drugs Annual: A world-wide yearly survey of new data and trends in adverse drug reactions. (1977)
John J B
The Vein Book (2007)
Etienne P A Neve et al.
PloS one, 10(9), e0138487-e0138487 (2015-09-18)
Recently two novel enzymes were identified in the outer mitochondrial membrane, mARC1 and mARC2. These molybdenum containing enzymes can reduce a variety of N-hydroxylated compounds, such as N-hydroxy-guanidines and sulfohydroxamic acids, as well as convert nitrite into nitric oxide (NO).
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持